Call for Abstracts

Abstract Submission Deadline: Monday, July 22
Late-Breaking Abstract Submission Deadline: Thursday, September 12
Advance Registration Deadline: Friday, September 13

Continuing Medical Education (CME) Activity—AMA PRA Category 1 Credits™ available
TABLE OF CONTENTS

Program Schedule ........................................ 2
Abstract Submission  
Categories and Guidelines ....................... 4
Late-Breaking Abstract  
Submission Guidelines ......................... 6
Accommodations and Travel ..................... 8
Continuing Medical Education ...............10
Financial Support for Attendance ..................11
Registration ..............................................12
Press ..........................................................13
General Information .........................14
Support Opportunities .........................16
Exhibit Information ..........................17
Webcasts of Sessions ..........................18
Registration Form ...........................19

About the Cover

1. The placenta and most cancers share the expression of a unique type of chondroitin sulfate, targetable by the malarial VAR2CSA protein. *Mol Cancer Res* December 1, 2016; 14(12):1288-1299.

2. Reduced number and impaired function of CD160+ natural killer (NK) cells in the tumor microenvironment contributes to the immune escape of human hepatocellular carcinoma. *Cancer Res* December 1, 2018; 78(23):6581-6593.

3. Here, molecular modeling has been used to generate a three-dimensional (3D) representation of a chemically modified, cholesterol-conjugated, self-delivering siRNA (hsiRNA). hsiRNAs are capable of rapid membrane association via cholesterol intercalation into lipid bilayers. *Mol Cancer Ther* June 1, 2018; 17(6):1251-1258.

ABOUT THE CONFERENCE ORGANIZERS

Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest scientific organization focused on every aspect of high-quality, innovative cancer research. Its reputation for scientific breadth and excellence attracts the premier researchers in the field. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers, and increase public understanding of cancer.

The mission of the AACR is to prevent and cure cancer through research, education, communication, and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

The National Cancer Institute (NCI), founded in 1937, is the U.S. Federal Government’s principal agency for cancer research and training. As the nation’s leading federal agency for cancer research, NCI has 30 divisions, offices, and centers that work together to build, maintain, and enhance a cohesive and comprehensive cancer research agenda. Their work ranges from cutting-edge research on cancer causes, treatment, and prevention; to training the next generation of cancer researchers; to funding and supporting the nation’s vast network of scientists and cancer research institutions; to informing and educating the American public and the world about cancer.

The aims of the European Organisation for Research and Treatment of Cancer (EORTC) are to develop, conduct, coordinate, and stimulate translational and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patient quality of life. Extensive and comprehensive research in this wide field is often beyond the means of individual European hospitals and can be best accomplished through the multidisciplinary multinational efforts of basic scientists and clinicians.

The ultimate goal of the EORTC is to improve the standard of cancer treatment through the testing of more effective therapeutic strategies based on drugs, surgery, and/or radiotherapy that are already in use. The EORTC also contributes to the development of new drugs and other innovative approaches in partnership with the pharmaceutical industry. This is accomplished mainly by conducting large, multicenter, prospective, randomized, phase III clinical trials. In this way, the EORTC facilitates the passage of experimental discoveries into state-of-the-art treatments.
ORGANIZING AND SCIENTIFIC COMMITTEES

ORGANIZING COMMITTEE COCHAIRS:

Elizabeth M. Jaffee  
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD (AACR)*

James H. Doroshow  
National Cancer Institute, Bethesda, MD (NCI)*

Denis A. Lacombe  
European Organisation for Research and Treatment of Cancer, Brussels, Belgium (EORTC)*

SCIENTIFIC COMMITTEE COCHAIRS:

William R. Sellers  
Broad Institute of MIT and Harvard, Cambridge, MA (AACR)*

James L. Gulley  
National Cancer Institute, Bethesda, MD (NCI)*

Emiliano Calvo  
START Madrid, Hospital de Madrid Norte Sanchinarro, Madrid, Spain (EORTC)*

SCIENTIFIC COMMITTEE:

Ana Carrizosa Anderson, Harvard Medical School, Brigham and Women's Hospital, Boston, MA
D. Allen Annis, Aileron Therapeutics, Watertown, MA
Ahmad Awada, Institut Jules Bordet, Brussels, Belgium
Udai Banerji, Institute of Cancer Research, London, United Kingdom
Sara J. Buhrlage, Dana-Farber Cancer Institute, Boston, MA
Jan Bussink, Radboud University Medical Center, Nijmegen, The Netherlands
Alice P. Chen, National Cancer Institute - Division of Cancer Treatment and Diagnosis, Bethesda, MD
Peter L. Choyke, National Cancer Institute - Center for Cancer Research, Bethesda, MD
Benjamin F. Cravatt, The Scripps Research Institute, La Jolla, CA
William L. Dahut, National Cancer Institute - Center for Cancer Research, Bethesda, MD
Kapil Dhingra, KAPital Consulting, Sparta, NJ
Susan M. Domchek, University of Pennsylvania, Philadelphia, PA
Janet F. Eary, National Cancer Institute - Division of Cancer Treatment and Diagnosis, Bethesda, MD
William D. Figg, National Cancer Institute - Center for Cancer Research, Bethesda, MD*
Lori S. Friedman, Genentech, Inc., South San Francisco, CA
Viktor Grünwald, University Hospital Essen, West German Cancer Center, Essen, Germany
W. Nicholas Haining, Merck & Company, Boston, MA
Lyndsay N. Harris, National Cancer Institute - Division of Cancer Treatment and Diagnosis, Bethesda, MD
Toby T. Hecht, National Cancer Institute - Division of Cancer Treatment and Diagnosis, Bethesda, MD
Stanley Lipkowitz, National Cancer Institute - Center for Cancer Research, Bethesda, MD*
Huiping Liu, Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
Martijn P.J.K. Lolkema, Erasmus University Medical Center, Rotterdam, The Netherlands
Christophe Massard, Institut Gustave Roussy, Villejuif, France
Marcela V. Maus, Massachusetts General Hospital, Boston, MA
Frank McCormick, USCF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Victor Moreno, START Madrid, Hospital Fundación Jiménez Díaz, Madrid, Spain
Jeffrey A. Moscow, National Cancer Institute - Division of Cancer Treatment and Diagnosis, Bethesda, MD
Andrea P. Myers, Novartis Institutes of BioMedical Research, Shanghai, China
Barry R. O'Keefe, National Cancer Institute - Center for Cancer Research, Bethesda, MD
Ruth Plummer, Northern Institute for Cancer Research, Newcastle, United Kingdom
Poliikos I. Poulikakos, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
Eric Raymond, Paris Saint-Joseph Hospital, Paris, France
Eytan Ruppin, National Cancer Institute - Center for Cancer Research, Bethesda, MD
Jean-Charles Soria, MedImmune, LLC, Gaithersburg, MD*
Patricia S. Steeg, National Cancer Institute - Center for Cancer Research, Bethesda, MD
Frank Stegmeier, KSQ Therapeutics, Cambridge, MA
Beverly A. Teicher, National Cancer Institute - Division of Cancer Treatment and Diagnosis, Bethesda, MD
Christopher R. Vakoc, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY*
Marcel Verheij, Radboud University Medical Center, Nijmegen, The Netherlands
Jaap Verweij, Erasmus University Medical Center, Rotterdam, The Netherlands*
Emile E. Voest, Netherlands Cancer Institute, Amsterdam, The Netherlands

*denotes member of the Executive Committee
### SATURDAY, OCTOBER 26

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 p.m.–4:45 p.m.</td>
<td>EDUCATIONAL SESSION: Targeting Molecular Subtypes: Successes and Failures</td>
</tr>
<tr>
<td>5:00 p.m.–5:10 p.m.</td>
<td>WELCOME AND OPENING REMARKS</td>
</tr>
<tr>
<td>5:15 p.m.–7:00 p.m.</td>
<td>KEYNOTE SESSION</td>
</tr>
<tr>
<td>7:00 p.m.–8:30 p.m.</td>
<td>OPENING RECEPTION</td>
</tr>
</tbody>
</table>

### SUNDAY, OCTOBER 27

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m.–8:00 a.m.</td>
<td>CONTINENTAL BREAKFAST</td>
</tr>
<tr>
<td>8:00 a.m.–9:45 a.m.</td>
<td>PLENARY SESSION 1: The Landscape of CAR-T Therapeutics</td>
</tr>
<tr>
<td>9:45 a.m.–10:00 a.m.</td>
<td>BREAK</td>
</tr>
<tr>
<td>10:00 a.m.–11:45 a.m.</td>
<td>PLENARY SESSION 2: From Glues to TACs: Redirecting Cellular Protein Degradation</td>
</tr>
<tr>
<td>11:50 a.m.–12:20 p.m.</td>
<td>SPOTLIGHT ON PROFFERED PAPERS 1</td>
</tr>
<tr>
<td>12:30 p.m.–4:00 p.m.</td>
<td>POSTER SESSION A / EXHIBIT SHOW</td>
</tr>
</tbody>
</table>

*Subject to change. Visit AACR.org/Targets19 for an updated program schedule.*
2:30 p.m.-3:30 p.m.  ACR CHEMISTRY IN CANCER RESEARCH (CICR) WORKING GROUP TOWN HALL

4:15 p.m.-6:00 p.m.  CONCURRENT SESSIONS 1-3
   CC1: Antibody Drug Conjugates/ Biotherapeutics
   CC2: CAR-T and Directed T-cell Therapy: Advancing Beyond B-ALL
   CC3: Unveiling the Landscape of Synthetic Lethal or Context-Dependent Targets

6:00 p.m.  EVENING OFF / DINNER ON OWN

TUESDAY, OCTOBER 29

7:00 a.m.-8:00 a.m.  CONTINENTAL BREAKFAST

8:00 a.m.-9:45 a.m.  PLENARY SESSION 5: Immuno-oncology

9:45 a.m.-10:00 a.m.  BREAK

10:00 a.m.-11:45 a.m.  PLENARY SESSION 6: Frontiers in Small-Molecule Drug Discovery

MONDAY, OCTOBER 28

7:00 a.m.-8:00 a.m.  CONTINENTAL BREAKFAST

8:00 a.m.-9:45 a.m.  PLENARY SESSION 3: Targeting DNA Repair, PARP, and Beyond

9:45 a.m.-10:00 a.m.  BREAK

10:00 a.m.-11:45 a.m.  PLENARY SESSION 4: The Role of Liquid Biopsies in Guiding Cancer Therapeutics: Detection, Response Monitoring, and Resistance

11:50 a.m.-12:20 p.m.  SPOTLIGHT ON PROFFERED PAPERS 2

12:30 p.m.-4:00 p.m.  POSTER SESSION C / EXHIBIT SHOW

WEDNESDAY, OCTOBER 30

6:30 p.m.-8:30 p.m.  AACR WOMEN IN CANCER RESEARCH (WICR) ANNIVERSARY SESSION

11:45 a.m.-12:00 p.m.  CLOSING REMARKS

12:00 p.m.  DEPARTURE

*Subject to change. Visit AACR.org/Targets19 for an updated program schedule.
When submitting an abstract for the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference using the Online Abstract Submission System, authors will be asked to choose the appropriate category that best describes the scientific content of the abstract. This information will be used as a guide by the members of the Scientific Committee in their review of abstracts. Before making a selection, authors should review the entire list below for the most appropriate abstract category.

Angiogenesis and antiangiogenesis agents
Animal models
Apoptosis, necrosis, and autophagy
Bioinformatics
Biomarkers
Cancer stem cells
Cell cycle regulators
Cellular responses to therapy
Chemistry
Chemoprevention
Clinical trials
DNA repair and modulation
Drug delivery
Drug design
Drug metabolism, transport, and biodistribution
Drug resistance and modifiers
Drug screening
EGFR/Her2
Epigenetic regulation of tumor immunity
Epigenetic targets
Gene therapies
Genomics, proteomics, and target discovery
Heat shock proteins
Hormonal agents and therapy
Imaging
Immune checkpoints
Immune mechanisms invoked by radiation therapy
Immune modulators
Immune monitoring/clinical correlates
Immune response to therapies
In vitro and in vivo models for targets
MAPK pathways
Metabolism
Metastasis and invasion
Molecular classification of tumors
Monoclonal antibodies
mTOR/PI3-kinase
Natural products
New molecular targets
Novel assay technology
Pediatric-early drug development
Pharmacogenetics, pharmacogenomics, and therapeutic response
Pharmacokinetics and pharmacodynamics
Protein-protein interaction
Radiotherapeutics
RNA and RNA-based technologies and therapies
Signal transduction modulators
Target identification and validation
Therapeutic agents: biological
Therapeutic agents: other
Therapeutic agents: small-molecule kinase inhibitors
Topoisomerase inhibitors
Toxicology
Tubulin-interacting agents
Tumor immunology targets
Tumor microenvironment
Tumor suppressors
Other
GUIDELINES FOR PREPARATION AND SUBMISSION OF ABSTRACTS
(Submission deadline: 11:59 p.m. U.S. Eastern Time, Monday, July 22, 2019)

Authors must submit abstracts for presentation at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference using the AACR Online Abstract Submission System, which is available at AACR.org/Targets19. You can create, modify, and submit abstracts until the Monday, July 22, submission deadline. Complete instructions on the use of the AACR Online Abstract Submission System are available online.

The Abstract Submission System has been optimized for the current versions of most browsers, including: Google Chrome version 40 or higher; Internet Explorer version 10 or higher; Firefox version 40 or higher; and Safari version 8.0 or higher. Browsers should be set to enable JavaScript and to accept cookies.

Users who need assistance in properly updating and configuring their browsers should contact Abstract Submission Customer Service at 866-341-9590 or MolecularTargets2019@mirasmart.com.

CONTENT OF ABSTRACTS
Authors who submit abstracts confirm that they have not previously published these data, that they have not previously presented them at a large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference. Each abstract should contain:
(a) an introductory sentence indicating the purposes of the study;
(b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions.

Authors must accept sole responsibility for the statements in their abstracts. Abstracts should be carefully proofread to avoid errors in the published literature. American spelling should be used throughout; for more information regarding American spelling, please refer to Scientific Style and Format: The CSE Manual for Authors, Editors, and Publishers, Eighth Edition (Council of Science Editors, 2014).

COPYRIGHT TRANSFER/ABSTRACT PRESENTATION
On behalf of all authors, the corresponding author must:
1. Transfer copyright of the abstract to the AACR for publication; and
2. Confirm that an author will attend the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference to present the abstract.

ABSTRACT CONTROL NUMBER
An abstract control number (e.g., 17-A-1234-AACR) will be assigned to each abstract submitted online and will be listed on all email correspondence regarding the abstract. Please refer to the Abstract Control Number in any abstract communications.

FINANCIAL RELATIONSHIPS OF COAUTHORS
Per ACCME regulations, the AACR must collect information on the financial relationships of all meeting presenters and abstract authors. Each author listed on the abstract will receive an e-mailed request to disclose their financial relationships. Abstracts cannot be sent out for review until disclosures have been received from all authors. For more information on financial relationships, visit AACR.org/CME.

LENGTH OF ABSTRACTS
The combined length of the abstract title and body may not exceed 3,000 characters, not including spaces and the author string. Submission cannot be completed for abstracts that exceed this limit.

DISCLOSURE OF CHEMICAL STRUCTURES
At the time of abstract submission, the submitting author is required to state whether chemical compounds were used in the scientific work to generate the data in the proffered paper. Chemical compounds are defined as low-molecular-weight (generally <1000 g/mol) organic or inorganic molecules, peptides, or proteins/nucleic acids co-crystallized with low-molecular-weight molecules. If chemical compounds were used, the corresponding author is further required to indicate whether the complete chemical structures of the compounds used will be disclosed at the time of presentation at the meeting. The chemical structures are not required to be included at the time of abstract submission; rather, an indication of the intent to disclose any such structures at the time of presentation is required. The Scientific Committee will then evaluate the information provided by the corresponding author and determine the acceptability of the proffered paper for presentation. Those who do not intend to disclose chemical structures may have their abstracts rejected for participation; however, a limited number of these abstracts may be accepted for presentation if deemed to be of sufficient scientific merit.

DEADLINE FOR WITHDRAWAL OF ABSTRACTS
The AACR cannot comply with any request for withdrawal of an abstract that will delay the publication of the Program. However, requests to withdraw abstracts will be accepted through Sunday, September 1, 2019. Withdrawal requests must be sent by email to abstractchanges@aacr.org. Withdrawal requests must include the abstract control number and title as well as an explanation of the reason for withdrawal.
GUIDELINES FOR PREPARATION AND SUBMISSION OF LATE-BREAKING ABSTRACTS


LATE-BREAKING ABSTRACT SUBMISSION PROCESS

Abstracts that contain new data (unavailable at the time of the July 22 regular submission deadline) may be submitted as late-breaking abstracts beginning on Tuesday, September 3, 2019. Submissions must be completed by Thursday, September 12. Late-breaking abstracts will be considered for both oral and poster presentations.

Authors must submit late-breaking abstracts for presentation at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference using the AACR Online Abstract Submission System, which will be available at AACR.org/Targets19 beginning Tuesday, September 3, 2019. You can create, modify, and submit abstracts until 11:59 p.m. U.S. Eastern Time on Thursday, September 12. Complete instructions on the use of the AACR Online Abstract Submission System will be provided online.

A special subcommittee of the Scientific Committee will evaluate the merit of late-breaking abstracts.

DEADLINE FOR WITHDRAWAL OF LATE-BREAKING ABSTRACTS

The AACR cannot comply with any request for withdrawal of a late-breaking abstract that will delay the publication of the Program. However, requests to withdraw abstracts will be accepted through Friday, September 27, 2019. Withdrawal requests must be sent by email to abstractchanges@aacr.org. Withdrawal requests must include the abstract control number and title as well as an explanation of the reason for withdrawal.

OPPORTUNITIES FOR SHORT TALKS FROM ABSTRACTS AND LATE-BREAKING ABSTRACTS

A subcommittee of the Scientific Committee will evaluate highly rated abstracts and late-breaking abstracts and, where thematically appropriate, invite authors to present a short talk during the program. All accepted abstracts are eligible. Not all sessions will include short talks.
RELEASE DATE FOR ABSTRACTS AND LATE-BREAKING ABSTRACTS

All accepted abstracts are scheduled to be posted online via the online planner and app on Wednesday, October 16, 2019 (with the exception of those abstracts and late-breaking abstracts selected for inclusion in the AACR press program). Accepted late-breaking abstracts will be posted on Friday, October 25. Abstracts will not be available before these dates.

PRESENTATION OF ABSTRACTS AND LATE-BREAKING ABSTRACTS

Every abstract and late-breaking abstract that has been accepted for publication in the online Proceedings must also be presented at the meeting. Specifically, the author listed as the presenter must register for the meeting and attend the session in which the abstract is scheduled to discuss in detail the research outlined in the published abstract, according to the specific guidelines of the session. If, due to unforeseen circumstances, the designated presenter is unavailable to attend the session to present the abstract, he or she must contact the AACR Program Development Department to designate a coauthor to serve as the presenter. If no authors are available to present the abstract, the presenter must withdraw the abstract by submitting a withdrawal request by email to abstractchanges@aacr.org. Withdrawal requests must include the abstract control number and title as well as an explanation of the reason for withdrawal.

Failure to comply with these regulations pertaining to abstract presentation may result in actions including, but not limited to:

• The withdrawal of the abstract or late-breaking abstract from the session
• The removal of the abstract or late-breaking abstract from the online Proceedings
• The loss of future abstract or late-breaking abstract submission/authorship privileges for the presenter of the abstract or late-breaking abstract
The conference will be held at the Hynes Convention Center, located in the heart of Boston’s historic Back Bay neighborhood and just 5 miles/8 km from Boston Logan International Airport.

The AACR has contracted with several hotels to offer reduced room rates for attendees at this year’s conference. The Sheraton Boston Hotel will serve as the headquarters hotel for the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference, with the Boston Marriott Copley Place and The Midtown Hotel also serving as official conference hotels. Please review the pricing options below and the map on page 11 before making reservations.

Hotel reservations can be made by phone or online through AACR Housing. AACR Housing will accept reservations through Tuesday, October 1, 2019. After October 1, reservations and rates will be subject to hotel availability. Room reservations must be guaranteed with a major credit card. To make a reservation please visit the Accommodations and Travel webpage at AACR.org/Targets19.

For more information on the convention center and conference hotels, please visit AACR.org/Targets19 and follow the link for Accommodations and Travel.

TRAVEL TO BOSTON

The closest major airport to the Convention Center and conference hotels is Boston’s Logan International Airport (BOS), located approximately 5 miles/8 km (15-20 minutes) from the Hynes Convention Center.

The AACR has chosen Corporate Traveler (CT) as its exclusive travel management partner. Conference attendees are welcomed to leverage AACR’s partnership with CT and utilize their services to make your travel arrangements.

Our dedicated Travel Manager at Corporate Traveler will offer personalized service and travel expertise to help travelers secure the most cost-effective and time-efficient itineraries. As a division of the leading global agency Flight Centre Travel Group, CT has access to a variety of exclusive international fares, and travelers will have access to an in-house team of skilled emergency support agents, available 24/7 from anywhere in the world at no extra cost. You will still be able to earn mileage credit for your frequent flyer programs.
AACR’s CT office is open Monday through Friday from 8 a.m. to 6 p.m. ET.

Email: garry.staegemann@corporatetraveler.us
Phone: (215) 825-3650
Toll-Free: +1 (888) 666-4209

You may also call United Airlines directly at (800) 521-4041, or book online and enter promo code ZG48729175. Please book early to take advantage of promotional fares that give you the greatest discount.

Amtrak train service is also readily available for attendees traveling from the Eastern U.S. to Boston. Amtrak’s Back Bay Station is approximately 1 mile from the Hynes Convention Center.

For additional information on travel to Boston and ground transportation once you arrive, please visit AACR.org/Targets19 and follow the link for Accommodations and Travel.

INTERNATIONAL TRAVEL

Researchers from more than 50 different countries around the world regularly participate in this joint AACR-NCI-EORTC conference. If you plan to attend the 2019 Molecular Targets and Cancer Therapeutics conference, please contact the American Consulate in your country to review the current regulations for travel to the United States. Obtaining the proper documentation may take several weeks or months, depending on your location, so please contact the consulate as soon as possible if you are considering attending this conference. Information is also available on the U.S. Department of State website at www.travel.state.gov.

Call for Abstracts | Abstract Deadline: July 22, 2019 | Late-Breaking Abstract Deadline: September 12, 2019
The AACR’s Continuing Medical Education (CME) Program brings the latest cancer research from “bench to bedside and back.” The AACR has been awarded Accreditation with Commendation status from the Accreditation Council for Continuing Medical Education (ACCME). The CME Program consists of educational interventions designed to encourage the analysis and discussion of the latest findings in all areas of basic, translational, and clinical cancer research not only among researchers, but also by engaging clinicians in this scientific discourse. The AACR is committed to advance the ability of clinicians to apply critical aspects of cancer research to the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer.

Continuing Medical Education Activity-AMA PRA Category 1 Credits™ will be available. Details will be available online at AACR.org/Targets19.
AACR SCHOLAR-IN-TRAINING AWARDS

AACR Associate Members in good standing who submit abstracts may be considered for a Scholar-in-Training Award to offset a portion of the registration, travel, and subsistence expenses incurred in attending this conference. The number of awards provided and the dollar amounts of each award will be based on available funding. The award application deadline is Monday, July 22, 2019. Additional information and application instructions will be available online at AACR.org/Targets19.

AACR MINORITY AND MINORITY-SERVING INSTITUTION (MMSI) FACULTY SCHOLAR IN CANCER RESEARCH AWARDS

Full-time minority faculty and faculty of Minority-Serving Institutions (Historically Black Colleges and Universities [HBCUs], Hispanic-Serving Institutions [HSIs], American Indian Tribally-Controlled Colleges and Universities [AITCCUs], and other postsecondary institutions as defined by the U.S. Department of Education) who present a proffered paper at this conference are encouraged to apply for this meritorious scholar award. Supported by a generous grant from the Center to Reduce Cancer Health Disparities of the National Cancer Institute, the purposes of these awards are to increase the scientific knowledge base of minority faculty and faculty at MSIs, to encourage them in their research, and to assist in inspiring their students to pursue careers in cancer research. Only citizens of the United States or Canada or scientists who are permanent residents of these countries may receive one of these awards. The award application deadline is Monday, July 22, 2019. Additional information and application instructions are available online at AACR.org/Targets19.

AACR MINORITY SCHOLAR IN CANCER RESEARCH AWARDS

Presenters of a proffered paper who are full-time predoctoral (graduate or medical) students, residents, and clinical or postdoctoral fellows who are engaged in cancer research or have the training and potential to make contributions to this field are encouraged to apply for this meritorious scholar award. Supported by a generous grant from the Center to Reduce Cancer Health Disparities of the National Cancer Institute, this program applies only to racial/ethnic minority groups that have been identified by the NCI as being traditionally under-represented in cancer and biomedical research, i.e., African American/Black, Alaskan Native, Hispanic/Latino, Native American, and Native Pacific Islander. Only citizens of the United States or Canada or scientists who are permanent residents of these countries may receive one of these awards. The award application deadline is Monday, July 22, 2019. Additional information and application instructions are available online at AACR.org/Targets19.
Individuals wishing to attend the conference can register online at AACR.org/Targets19 or by returning the registration form on pages 19-20 of this brochure. Attendee registration includes admission to all scientific sessions, poster sessions, the opening reception on October 26, conference continental breakfasts on October 27, 28, 29, and 30, and coffee breaks. Registration also provides individual access to the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Webcast and one complimentary drink ticket to the opening reception on October 26.

All registrants agree to follow the Code of Conduct, Policies, and Procedures for the conference outlined on page 15 of this brochure. Registration will not be processed without full payment. Government or other payment orders are not accepted. All payments must be in U.S. currency, drawn on a U.S. bank. Visa, MasterCard, and American Express are also accepted for payment. Places at the conference are on a first-come, first-served basis, according to the date of registration. On-site registration will be available at the Hynes Convention Center beginning Saturday, October 26 at 12:00 p.m. All registrations are for the full conference.

<table>
<thead>
<tr>
<th>ACR and EORTC Members</th>
<th>Advance Registration Until Sept. 13</th>
<th>Regular Registration After Sept. 13</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active/Affiliate (Nonprofit)</td>
<td>$850</td>
<td>$1,050</td>
</tr>
<tr>
<td>Active/Affiliate (Industry)</td>
<td>$1,025</td>
<td>$1,335</td>
</tr>
<tr>
<td>Associate (predoctoral students,</td>
<td>$530</td>
<td>$685</td>
</tr>
<tr>
<td>postdoctoral and clinical fellows)</td>
<td>$300</td>
<td>$400</td>
</tr>
<tr>
<td>Patient Advocate¹</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For nonmember advocate registration, email advocacy@aacr.org.

Nonmember pre-/postdoctoral students must have their registrar, dean, or department head certify that they are enrolled at the university and working toward a degree or fellowship in a field related to cancer research.

Requests for refunds must be made in writing and received by Friday, September 20, 2019. Refund requests may be sent by email to molecular@compusystems.com. There will be a $125 administrative fee for processing cancellations received by September 20. After September 20, no refunds can be made.

SURVIVOR AND PATIENT ADVOCATE OPPORTUNITIES

The AACR strongly encourages the involvement of survivors and patient advocates in this conference and is pleased to offer discounted registration rates to this group. Advocates must submit a biography or a curriculum vitae and the advocate verification form to receive the discounted rate. You can find the advocate verification form online at AACR.org/SurvivorsAndAdvocates. Please contact Karen Russell Mills at advocacy@aacr.org or 215-446-7104 for further information. On-site registration at this special rate will not be available.
Members of the national and international media rely on the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference to provide the most up-to-date information on drug development in oncology. At this year’s conference, the American Association for Cancer Research (AACR) Communications and Public Relations Department will be conducting a press program to highlight exciting cancer science. Reporters and PIOs from cancer and medical centers who are interested in registering for the conference should contact Charmaine Riley at charmaine.riley@aacr.org. The AACR does not release media lists, but will make available company-sponsored press releases on abstract presentations upon request. For more information on the Molecular Targets and Cancer Therapeutics press program, contact Rachel Salis-Silverman at rachel.silverman@aacr.org or 215-446-7159; Sarah Cohn at sarah.cohn@aacr.org or 215-446-8754; or Charmaine Riley at charmaine.riley@aacr.org or 215-309-4347.
AACR MEMBERSHIP

AACR membership is available to individuals who are interested in joining the AACR and being a part of a dynamic and vibrant organization that offers its members benefits, programs, and activities that promote the exchange of timely scientific information and excellent opportunities to participate more fully in the global conquest of cancer by fostering important relationships and collaborations with cancer scientists internationally. The AACR is also eager to support the exchange of knowledge and research with investigators who are in countries with emerging economies. Significantly reduced membership dues are available for these investigators.

ELIGIBILITY FOR REGISTRATION AT AACR AND EORTC MEMBER RATES

Nonmember individuals interested in joining the AACR and registering at the advance registration rate must submit membership applications no later than September 6, 2019. Only individuals who are listed on the membership rolls as members in good standing as of October 11, 2019, will be accorded the privilege of registering for the conference at the member rates noted on the registration form. If, upon review of the membership application, a candidate is deemed ineligible for the membership category to which he or she has applied, then the candidate will need to register at the nonmember rate. Membership information and the Membership Application form can be downloaded from the AACR website at AACR.org/Membership. Contact the Membership Department at 215-440-9300 or membership@aacr.org with any questions.

ASSISTANCE FOR ATTENDEES WITH DISABILITIES

This AACR-NCI-EORTC conference is accessible to all registrants. Attendees with special requirements for transportation, hotel accommodations, or other facilities associated with the conference should notify the AACR in advance when registering or by emailing meetings@aacr.org.
LOCATION

The conference will be held at the John B. Hynes Veterans Memorial Convention Center (the Hynes Convention Center), located in Boston’s Back Bay area. The Center is conveniently located close to public transportation for easy access by Boston’s “T” subway system and commuter rails. In many ways, the Hynes Convention Center is a city within a city. The Hynes is connected to not one, but two major retail complexes, Prudential Center and Copley Place, that contain just about everything attendees need during the conference. Fast food, fine dining, sundries, personal services, and world-class shopping—all under one roof. Attendees can experience Boston without ever worrying about the weather! Enter the Prudential Center through the Hynes South Lobby. Turn right for the Sheraton Boston Hotel, Starbucks, dining, and business center. A left turn leads to the Prudential Center, home to an extensive food court and fine dining, boutiques and shops including Saks Fifth Avenue and Lord & Taylor.

Boston attractions provide more compelling things to see and do than any other convention city in North America, from America’s history found along the Freedom Trail to world-famous museums and international cuisine. The Theater District, located only minutes from the Hynes Center, hosts Broadway plays and musicals. Jazz clubs, dance clubs, comedy clubs, and improv theaters add to the entertainment scene. And for those who consider shopping to be the ultimate entertainment, Boston offers the boutiques of Newbury Street and the shops at Quincy Market.

CODE OF CONDUCT, POLICIES, AND PROCEDURES

The AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference will bring together an estimated 2,500 representatives from academia, industry, government, and advocacy organizations from across the globe. In order for all participants to have the opportunity to gain the most benefit from this conference, the AACR is committed to providing a safe and secure environment. Please review the following policies and procedures for conference participants. By registering for the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics meeting, you agree to the following terms:

- The AACR prohibits intimidating, threatening, or harassing conduct of any kind during this program. This applies to all participants—attendees, presenters, exhibitors, staff, vendors, etc.

- The AACR is committed to a safe, hospitable, and productive environment for all participants of this program, regardless of age, disability, ethnicity, gender, religion, or sexual orientation.

- The AACR expects all participants to communicate professionally and constructively, handling dissent and disagreement with courtesy, dignity, and an open mind, being respectful when providing feedback and being open to alternate points of view.

- Children under 12 years of age are not permitted in any scientific session, poster session, the Exhibit Hall, or any official event taking place at this program at any time. Children cannot be left unattended or unsupervised in the Convention Center.

- Cell phones and other electronic devices must be turned off or placed on “silent” mode before entering a session. Participants should step out of session rooms to make calls or send emails or texts as the back lighting on electronic devices is distracting to other participants.

- The AACR expects participants to share information about this program responsibly and clearly distinguish individual opinion from fact.

- Participants must obey all applicable laws and regulations of the relevant government authorities while attending this program. Participants must comply with all applicable safety guidelines related to the conference venue.

- If a session room becomes too crowded, the AACR asks you to follow instructions provided by the AACR staff, Convention Center staff, or security. Instructions may include not standing against the walls, not blocking the aisles or doors, or being denied entry if the room becomes too crowded. The AACR and all participants are obligated to abide by the guidelines established by the Fire Marshal in the Convention Center. If a room reaches full capacity and there is not full cooperation, the Fire Marshal has the authority to delay or terminate the conference.

- The AACR encourages responsible drinking for those drinking alcohol. Beer and wine will be offered at some official events throughout this program. Alcohol will not be served to anyone under the age of 21. Alcoholic beverages are allowed in specific areas and must not be taken out of these areas.
SUPPORT OPPORTUNITIES

The AACR Foundation welcomes support from individuals, foundations, corporations, and other organizations interested in bringing this important international education program to participants from across the U.S. and the world. Our conference supporters enjoy recognition in the Molecular Targets and Cancer Therapeutics program, as well as acknowledgment on the AACR website promoting the conference. Additionally, the AACR Foundation acknowledges your generous support in on-site signage throughout the conference venue. At the conference, you will enjoy interacting face to face with cancer research professionals—academics, scientists, and pharmaceutical industry representatives—to discuss innovations in drug development, target selection, and the impact of new discoveries in molecular biology.

For information about supporting this important conference, please contact:

**AACR FOUNDATION**

Peter VanPelt, Senior Director  
Corporate and Foundation Relations  
peter.vanpelt@aacr.org  
215-446-7256

**PROFESSIONAL EDUCATIONAL GRANTS CONTINUING MEDICAL EDUCATION (CME)**

Ronald Arthur, Assistant Director  
Office of CME  
ronald.arthur@aacr.org  
215-446-7139
EXHIBIT INFORMATION

Opportunities are available to reserve an exhibit space at this conference. Over 2,000 scientists and researchers who are leading the discovery and drug development effort against cancer worldwide are expected to attend this year’s conference. Don’t miss this opportunity to further your business by meeting new contacts from industry, government, and academia. AACR Annual Meeting Exhibitors receive an additional priority point for reserving a booth at this conference. Booths are assigned on a first-come, first-served basis, so be sure to get your application in before space is sold out. For further information please contact LaShanna Mackey, AACR Senior Meetings and Exhibits Coordinator, at 215-440-9300 or exhibits@aacr.org.
FREE ACCESS FOR CONFERENCE REGISTRANTS

As in previous years, the AACR will make a limited number of selected session webcasts available free to all interested researchers. In addition, all paid registrants will receive exclusive online streaming access to the audio and slides of all scientific sessions presented at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference.*

Webcast features include:

- Available on compatible mobile devices and smart phones such as Android, iPad, iPod Touch, and iPhone
- Presentations searchable by session title, presentation title, and speaker name
- Exclusive access to online content for 15 months after the conference

* Participation in the 2019 Molecular Targets and Cancer Therapeutics webcasts is left to the discretion of each speaker. As a result, some presentations may not be available for webcast, and some webcast presentations may not include all slides. Sessions will not be streamed live. Selected session webcasts will be made available free within 24 hours, and the remaining webcasts will be made available to registrants on November 13, 2019. Registrants will receive login information via email on that date.
Name and Address Information
Check here if you are a member of: 🟢 AACR Membership # ____________ 🟠 EORTC
ADR    🟠 Nonmember
Dr.        Mr.        Ms.
Last/Family Name
First Name/Middle Initial
Title/Position
Department/Division Institution
Street/Building or Post Office Box
City/State or Province
Zip or Postal Code/Country
Telephone Fax
Email

☐ If you will require special accommodations, please specify: ________________________________

Nonmember Predoctoral Student/Postdoctoral and Clinical Fellow Certification
“I certify that the above named person is presently enrolled at this University and working toward a degree or fellowship in a field related to cancer research.”
Graduate Student 🟢 Medical Student 🟠 Postdoctoral Fellow 🟠 Clinical Fellow
Resident

Name (Registrar, Dean, or Dept. Head)
Signature (Registrar, Dean, or Dept. Head)
Title
University

Regrettant Profile (*required)
Highest Degree (check all that apply): 🟢 MD 🟠 PhD 🟠 PharmaD 🟠 DSc
☐ Other (please specify) ________________________________

Major Focus* (please check only one):
Advocacy 🟠 Clinical Practice 🟠 Research Administration
Basic Science 🟠 Clinical Research 🟠 Science Education
Business Development 🟠 Population Science 🟠 Translational Research
☐ Other (please specify) ________________________________

Research Areas of Expertise/Interest* (select all that apply):
Behavioral Science 🟠 Geriatrics 🟠 Hematology
Biochemistry and Biophysics 🟠 Immunology and Immuno-oncology
Bioinformatics and Computational Biology 🟠 Molecular Biology
Biostatistics in Clinical Trials 🟠 Pathology
Cancer Disparities Research 🟠 Pediatric Oncology
Carcinogenesis 🟠 Pharmacology
Cell Biology 🟠 Prevention and Intervention Research
Chemistry 🟠 Proteomics
Clinical Trials/Clinical Research 🟠 Radiation Science and Medicine
Diagnostics, Biomarkers, Imaging, and Early Detection 🟠 Surgical Oncology
Endocrinology 🟠 Survivorship Research
Epidemiology 🟠 Systems Biology and Convergence Science
Epigenetics/Epigenomics 🟠 Tumor Biology
Experimental and Molecular Therapeutics 🟠 Virology
Genetics 🟠 Other (please specify) ________________________________

Work Setting* (please check only one):
Academia/Cancer Center 🟠 Industry/Private Sector
Advocacy 🟠 Nonprofit Research Institute
Foundation/Advocacy Organization 🟠 Private Practice
Government 🟠 Professional Organization
Hospital/Clinic 🟠 Other (please specify) ________________________________

Information concerning gender and ethnic background is requested only to enable the AACR to ensure that its programs are serving all members of its diverse cancer research community.

Race or Ethnic Background (check only one):
☐ African American/Black 🟠 Caucasian
Alaskan Native 🟠 Hispanic/Latino
Asian 🟠 Native American
Asian American 🟠 Native Hawaiian/Pacific Islander
☐ Other (please specify) ________________________________

Gender: ☐ Male ☐ Female
MOLECULAR TARGETS AND CANCER THERAPEUTICS
REGISTRATION FORM

Registration Rates
(Includes full individual access to the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Webcast)

<table>
<thead>
<tr>
<th></th>
<th>Advance September 13</th>
<th>Regular/Onsite After September 13</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AACR and EORTC Members</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active/Affiliate (Nonprofit)</td>
<td>$850</td>
<td>$1,050</td>
</tr>
<tr>
<td>Active/Affiliate (Industry)</td>
<td>$1,025</td>
<td>$1,335</td>
</tr>
<tr>
<td>Associate (Pre-/Postdoctoral Student and Clinical Fellows)</td>
<td>$530</td>
<td>$685</td>
</tr>
<tr>
<td>Patient Advocate</td>
<td>$300</td>
<td>$400</td>
</tr>
<tr>
<td><strong>Nonmembers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonprofit</td>
<td>$1,125</td>
<td>$1,285</td>
</tr>
<tr>
<td>Industry</td>
<td>$1,355</td>
<td>$1,590</td>
</tr>
<tr>
<td>Pre-/Postdoctoral Student¹</td>
<td>$645</td>
<td>$790</td>
</tr>
</tbody>
</table>

TOTAL ENCLOSED OR CHARGED US$

Nonmember individuals interested in joining AACR and registering at the advance registration rate must submit applications no later than **September 6, 2019**. Only individuals who are listed on the membership rolls as of **October 11, 2019**, will be accorded the privilege of registering for the conference at the member rates noted on the registration form. If, upon review of the membership application, a candidate is deemed ineligible for the membership category to which he or she has applied, then the candidate will need to register at the nonmember rate. Membership information and the application form can be downloaded from the AACR website at AACR.org/Membership. Contact the AACR Membership Department at 215-440-9300 or membership@aacr.org with any questions.

Refund Policy: Requests for refunds must be made in writing. There will be a $125 processing fee for cancellations until **September 20, 2019**. After September 20, no refunds can be given.

Financial Support for Attendance: The AACR is pleased to provide financial assistance to eligible investigators for participation in this conference, subject to availability of funding. Additional information including award application instructions are available on the Financial Support for Attendance webpage for this conference.

¹For nonmember advocate registration information, email advocacy@aacr.org.
²Nonmember pre-/postdoctoral students must have their registrar, dean, or department head certify that they are enrolled at the university and working toward a degree or fellowship in a field related to cancer research.

Method of Payment

- Check or money order enclosed, payable to American Association for Cancer Research, drawn on a U.S. bank.
- VISA  MasterCard  American Express

Card#  CSC/CVV#  Expiration Date

Print Name of Cardholder

Signature of Cardholder

Registration fees are payable in U.S. dollars only. Personal checks are acceptable if payable through a U.S. bank.

Return to:

**2019 Molecular Targets**
Compusystems
2651 Warrenville Road
Suite 400
Downers Grove, IL 60515
708-344-4444 Fax
2019-2020 SCIENTIFIC CONFERENCES

Pancratic Cancer: Advances in Science and Clinical Care
Conference Cochairs: Dafna Bar-Sagi, Luis A. Diaz, Elizabeth M. Jaffee, and Brian M. Wolpin
September 6-9, 2019 | Boston, MA

Advances in Ovarian Cancer Research
Conference Cochairs: David D. L. Bowtell, George Coukos, Alan D. D’Andrea, and Karen H. Lu
September 13-16, 2019 | Atlanta, GA

Advances in Pediatric Cancer Research
Conference Cochairs: Crystal Mackall, David Malkin, Stefan Pfister, and Kimberly Stegmaier
September 17-20, 2019 | Montreal, QC, Canada

12th AACR Conference on
The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved
Conference Chair: Laura Fejerman
September 20-23, 2019 | San Francisco, CA

Fifth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
Conference Cochairs: Christoph Huber, Guido Kroemer, Ellen Puré, and Giorgio Trinchieri
September 25-28, 2019 | Paris, France

Cancer Research UK-AACR Joint Conference: Engineering and Physical Sciences in Oncology
Conference Cochairs: Sangeeta N. Bhatia, Kevin M. Brindle, Joe W. Gray, and Molly Stevens
October 15-17, 2019 | London, United Kingdom

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Scientific Committee Cochairs: William R. Sellers, James L. Gulley, and Emiliano Calvo
October 26-30, 2019 | Boston, MA

AACR International Conference: Infection and Cancer
Conference Chair: Tak W. Mak
Conference Cochairs: Anthony T. C. Chan, Suet Yi Leung, Douglas R. Lowy, and Andrew X. Zhu
November 8-10, 2019 | Hong Kong

Tumor Immunology and Immunotherapy
Conference Cochairs: Timothy A. Chan, Charles G. Drake, Marcela V. Maus, and Arlene H. Sharpe
November 17-20, 2019 | Boston, MA

San Antonio Breast Cancer Symposium
Presented by CTRC-AACR-BCM
Codirectors: Carlos L. Arteaga, Virginia G. Kaklamani, and C. Kent Osborne
December 10-14, 2019 | San Antonio, TX

Advancing Precision Medicine Drug Development: Incorporation of Real World Data and Other Novel Strategies
Conference Cochairs: David M. Hyman, Elaine R. Mardis, Lillian L. Siu, and Eliezer M. Van Allen
January 9-12, 2020 | San Diego, CA

Early Detection, Liquid Biopsies, and Minimal Residual Disease
Conference Cochairs: Luis A. Diaz, Jr., Maximilian Diehn, Irene M. Ghobrial, and Nicholas C. Turner
January 13-16, 2020 | Miami, FL

The Microbiome and Viruses
Conference Cochairs: Cynthia L. Sears, Giorgio Trinchieri, Jennifer A. Wargo, and Laurence Zitvogel
February 21-24, 2020 | Orlando, FL

The Evolving Landscape of Cancer Modeling
Conference Cochairs: Cory Abate-Shen, Andrea Califano, Jos Jonkers, and Calvin J. Kuo
March 2-5, 2020 | San Diego, CA

Evolutionary Dynamics in Carcinogenesis and Response to Therapy
Conference Cochairs: James DeGregori, Marco Gerlinger, Robert Gillies, and Andriy Marusyk
March 12-15, 2020 | Denver, CO

Advances in Prostate Cancer Research
Conference Cochairs: Felix Y. Feng, Karen E. Knudsen, and Scott A. Tomlins
March 12-15, 2020 | Denver, CO

AACR Annual Meeting 2020
Program Committee Chair: Antoni Ribas
April 24-29, 2020 | San Diego, CA